Abstract 137P
Background
Despite outcomes in pediatric B-cell acute lymphoblastic leukemia (B-ALL) haing improved greatly in the past decades, 10-15% of patients will still experience an event after initial complete remission. In this context, identification of new outcome predictors and therapeutic targets is still needed. For that purpose, here we studied long non-coding RNAs (lncRNAs) as potential novel biomarkers and outcome predictors in pediatric B-ALL.
Methods
Total RNA, extracted from tumor samples at diagnosis of 50 patients from three different Spanish hospitals (development cohort, DC) and 72 samples from CHU Sainte-Justine hospital in Montreal, Canada (validation cohort, VC), was sequenced on NovaSeq 6000 System (Illumina), with a mean depth of ≈180 million paired-reads. Reads were aligned with STAR and quantified with featureCounts using lncRNAKB annotation (hg38). Univariate Cox Proportional Hazard Models (UVC) were used to identify significant genes (p < .01 & HR > 1) for five-year Event-Free Survival (EFS) in each cohort. Then, different EFS prediction models were adjusted from overlapping genes in the DC and validated in the VC. The best model was selected based on overall performance, assessed using metrics such as AUC, concordance and scaled Brier score. Finally, patients were grouped in very high-risk (R1, highest 10% predicted risk samples), high-risk (R2, next 20% highest predicted risk samples), or standard-risk (R3, lowest 70% predicted risk samples) groups to perform Kaplan-Meier (KM) survival curves.
Results
UVC resulted in 769 and 1686 significant genes for DC and VC, respectively, from which 47 were common (42 lncRNAs). Starting from those 47 genes, a model with 19 genes (16 lncRNAs) was selected. In the DC 100% of R1 patients, 20% from R2, and none of the patients from R3 group reported an event during first five years of follow-up. In the VC, 87.5% of patients from R1 had an event, 28.6% from R2, and just one patient (2%) from R3 group; being both analyses significant (p <00001) in KM analyses.
Conclusions
Our EFS prediction model is able to significantly discriminate risk groups predicting an event during the first five years of follow-up from diagnosis, being a potential prognostic predictor tool in the near precision oncology future.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Eusko Jaurlaritza (Basque Government).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract